Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Semin Arthritis Rheum. 2024 Dec;69:152562. doi: 10.1016/j.semarthrit.2024.152562. Epub 2024 Oct 4.
Abatacept is a biological DMARD that has been used for the treatment of rheumatoid arthritis. However, the literature on its use in preclinical Rheumatoid arthritis (RA) is limited. We conducted this meta-analysis to evaluate the safety and efficacy of abatacept in preclinical RA.
This meta-analysis intends to assess the effectiveness and safety of abatacept in persons who are at a high risk of developing rheumatoid arthritis (RA) during the pre-clinical phase. The analysis comprises of three randomized controlled trials (RCTs) involving atotal of 367 participants. The study follows the procedures specified in the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA statemen RESULTS: The meta-analysis found that abatacept significantly reduced the risk of developing RA compared to placebo (RR: 0.67; 95 % CI: 0.51 to 0.89; P = 0.006) and improved tender joint count (SMD: -0.40; 95 % CI: -0.63 to -0.18; P = 0.0004). Additionally, abatacept demonstrated a significant reduction in functional disability (SMD: -1.51; 95 % CI: -1.91 to -1.11; P < 0.00001), though no significant difference was observed in pain reduction. Safety analysis revealed no significant differences in the occurrence of infections, malignancy, or discontinuation due to adverse events between the abatacept and placebo groups.
Abatacept is a promising treatment option for slowing down the development of RA in people who are at high risk. It has a positive safety profile. Additional studies with extended follow-up periods are required to validate these findings and offer more substantial data.
阿巴西普是一种生物 DMARD，已被用于治疗类风湿关节炎。然而，关于其在类风湿关节炎（RA）前临床应用的文献有限。我们进行了这项荟萃分析，以评估阿巴西普在类风湿关节炎前临床阶段的安全性和疗效。
本荟萃分析旨在评估阿巴西普在具有发生类风湿关节炎（RA）高风险的前临床阶段人群中的有效性和安全性。该分析包括三项涉及 367 名参与者的随机对照试验（RCT）。研究遵循《Cochrane 系统评价干预手册》和 PRISMA 声明中规定的程序。
荟萃分析发现，与安慰剂相比，阿巴西普显著降低了发生 RA 的风险（RR：0.67；95 % CI：0.51 至 0.89；P = 0.006），并改善了压痛关节计数（SMD：-0.40；95 % CI：-0.63 至 -0.18；P = 0.0004）。此外，阿巴西普在降低功能障碍方面也显示出显著效果（SMD：-1.51；95 % CI：-1.91 至 -1.11；P < 0.00001），但在减轻疼痛方面没有显著差异。安全性分析显示，阿巴西普组和安慰剂组在感染、恶性肿瘤或因不良事件停药的发生率方面无显著差异。
阿巴西普是一种有前途的治疗选择，可以减缓高危人群中 RA 的发展。它具有良好的安全性。需要进行更多具有延长随访期的研究来验证这些发现并提供更充分的数据。
